90
Participants
Start Date
April 30, 2021
Primary Completion Date
November 30, 2022
Study Completion Date
November 30, 2022
Cannabidiol, pharmaceutically produced with < 5 ppm THC
CardiolRx 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
Placebo
Placebo 2.5 mg/kg to 7.5 mg/kg of body weight b.i.d taken orally with food
SVRI- Irmandade de Santa Casa de Misercordia de Santos, Jabaquara
Science Valley Research Institute, Santo André
Complexo Hospitalar de Niteroi- Centro de Pesquisa Clinica, Rio de Janeiro
Westchester General Hospital, Miami
JY Research Institute, Cutler Bay
University of South Florida, Tampa
Prairie Education and Research Cooperative, Springfield
TecSalud, Monterrey
Baylor Scott & White Health - Temple, Temple
University of Texas Health Science Center, San Antonio
Science Valley Research Institute, Campo Largo
Valleywise Health Medical Center, Phoenix
Universidade Estadual de Maringa, Maringá
Hospital São Lucas PUCRS, Porto Alegre
Irmandade Santa Casa de Misericórdia, Porto Alegre
Núcleo de Ensino e Pesquisa do Instituto Mário Penna, Conjunto ACM
Fundação Pio XII - Hospital de Amor Barretos, Barretos
IPECC-Instituto de Pesquisa Clínica de Campinas, Campinas
Instituto do Coração do HCFMUSP, Cerqueira César
Fundação Faculdade Regional de Medicine de Sao Jose do Rio Preto (SJRP), São José do Rio Preto
Lead Sponsor
Cardiol Therapeutics Inc.
INDUSTRY